Wenqi Gan
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Wenqi Gan is an Associate Professor at the University of Connecticut School of Medicine in the United States. His research focuses on public health issues, particularly the risk of overdose-related deaths among individuals with a history of incarceration and the impact of environmental factors such as snowfall and temperature on myocardial infarction mortality. Through his work, he aims to contribute to the understanding of health disparities and environmental health risks.
Articles (6)
Year:
2026
Monocytes are critical in controlling tissue infections and inflammation. Monocyte dysfunction contributes to the inflammatory pathogenesis of cystic fibrosis (CF) caused by CF transmembrane conductance regulator (CFTR) mutations, making CF a clinically relevant disease model for studying the contribution of monocytes to inflammation. Although CF monocytes exhibited adhesion defects, the precise mechanism is unclear. Herein, superresolution microscopy showed that an integrin clustering but not an integrin activation defect determines the adhesion defect in CFTR-deficient monocytes, challenging the existing paradigm emphasizing an integrin activation defect in CF patient monocytes. We further found that the clustering defect is accompanied by defects in CORO1A membrane recruitment, actin cortex formation, and CORO1A engagement with integrins. Complementing canonical studies of leukocyte adhesion focusing on integrin activation, we highlight the importance of integrin clustering in cell adhesion and report that integrin clustering and activation are distinctly regulated, warranting further investigation for selective targeting in therapeutic strategy design involving leukocyte-dependent inflammation.
Year:
2025
Background: Pathologic complete response (pCR) is utilized as a surrogate for breast cancer outcomes in high-risk patients with breast cancer. Racial disparities in pCR have been assessed by clinical trial data, the National Cancer Database, and single-center experiences; however, results vary by setting. This population study using the Surveillance, Epidemiology, and End Results (SEER) Program aims to assess differences in pCR rates between Black and White women after neoadjuvant chemotherapy and assess survival by race and pCR status. Methods: This is a population-based cohort study utilizing SEER. Black and White women with nonmetastatic breast cancer diagnoses who received neoadjuvant chemotherapy between 2010 and 2018 were included. Results: A total of 10,254 patients were analyzed. Black women had lower odds of pCR compared with White women (adjusted OR, 0.85; 95% confidence interval, 0.76–0.95). With a median follow-up of 5.2 years, there was no difference in the adjusted risk of breast cancer–related or all-cause mortality between races when pCR was achieved. However, among patients who did not achieve pCR, Blacks had higher breast cancer–related and all-cause mortality risk. Conclusions: Utilizing real-world data, Black women had lower odds of pCR than White women, and non-pCR Black women had worse survival outcomes than non-pCR White women. Impact: pCR alone can affect survival outcomes in Black and White women. Outside of clinical trials, racial disadvantages are clear. These findings highlight the need for interventions so that all patients receive optimal treatment to help mitigate breast cancer survival disparities.
Year:
2025
Background: Pathologic complete response (pCR) is utilized as a surrogate for breast cancer outcomes in high-risk patients with breast cancer. Racial disparities in pCR have been assessed by clinical trial data, the National Cancer Database, and single-center experiences; however, results vary by setting. This population study using the Surveillance, Epidemiology, and End Results (SEER) Program aims to assess differences in pCR rates between Black and White women after neoadjuvant chemotherapy and assess survival by race and pCR status. Methods: This is a population-based cohort study utilizing SEER. Black and White women with nonmetastatic breast cancer diagnoses who received neoadjuvant chemotherapy between 2010 and 2018 were included. Results: A total of 10,254 patients were analyzed. Black women had lower odds of pCR compared with White women (adjusted OR, 0.85; 95% confidence interval, 0.76–0.95). With a median follow-up of 5.2 years, there was no difference in the adjusted risk of breast cancer–related or all-cause mortality between races when pCR was achieved. However, among patients who did not achieve pCR, Blacks had higher breast cancer–related and all-cause mortality risk. Conclusions: Utilizing real-world data, Black women had lower odds of pCR than White women, and non-pCR Black women had worse survival outcomes than non-pCR White women. Impact: pCR alone can affect survival outcomes in Black and White women. Outside of clinical trials, racial disadvantages are clear. These findings highlight the need for interventions so that all patients receive optimal treatment to help mitigate breast cancer survival disparities.
Year:
2025
Year:
2020
Year:
2020
Collaborators (6)
Zhichao Fan
Assistant Professor
University of Connecticut Health Center
Kurt T Schalper
Graduate Assistant
University of Connecticut Health Center
Changchun Liu
Professor
University of Connecticut Health Center
Yunfeng Chen
Assistant Professor
University of Texas Medical Branch at Galveston
Beiyan Zhou
Professor
University of Connecticut Health Center
Emanuela M Bruscia
Associate Professor
Yale University
Make your next move.
Prepare your application
Review drafts before you send them.